quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:50:17·70d
INSIDERFiling
Rigel Pharmaceuticals Inc. logo

EVP, Chief Medical Officer Rojkjaer Lisa covered exercise/tax liability with 3,758 shares, decreasing direct ownership by 19% to 15,959 units (SEC Form 4)

RIGL· Rigel Pharmaceuticals Inc.
Health Care
Original source

Companies

  • RIGL
    Rigel Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Nov 5UpdateJefferies$42.00
  • Apr 3UpdatePiper Sandler$2.00
  • Jun 9UpdateCitigroup-
  • Jun 8UpdatePiper Sandler$1.00
  • Jun 8UpdateCantor Fitzgerald$1.00
  • Mar 23UpdateB. Riley Securities$4.00

Related

  • SEC2d
    Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement
  • PR17d
    Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
  • SEC20d
    SEC Form DEFA14A filed by Rigel Pharmaceuticals Inc.
  • SEC20d
    SEC Form DEF 14A filed by Rigel Pharmaceuticals Inc.
  • PR24d
    Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO® (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology
  • SEC27d
    Amendment: SEC Form SCHEDULE 13G/A filed by Rigel Pharmaceuticals Inc.
  • SEC51d
    Rigel Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
  • SEC51d
    SEC Form 10-K filed by Rigel Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022